FGF21型
功能(生物学)
细胞生物学
细胞内
化学
分泌途径
兴奋剂
分泌物
抑制器
胰岛素
非规范的
信号转导
下调和上调
生产(经济)
作者
Xinyue Liao,Tianjiao Wei,Qi Wu,Deshan Yin,Li Xia,Fei Li,Kun Yang,Xiaona Cui,Jin Yang,Tianpei Hong,Rui Wei
标识
DOI:10.1016/j.apsb.2026.10.037
摘要
Homotypic cell-to-cell communication among pancreatic endocrine cells regulates β -cell function. However, the potential secretory factors and mechanisms await further elucidation. Herein, fibroblast growth factor 21 (FGF21) is identified as a β -cell-derived factor induced by glucagon-like peptide-1 (GLP-1) in mouse islets and β -cells. FGF21 production in β -cells is dependent on GLP-1 receptor, which is confirmed by using gene knockout and pharmacological blockade. β -Cell-specific knockout of Fgf21 impairs the glucose-lowering effect and β -cell function improvement induced by GLP-1. Pharmacological or genetic inhibition of β -Klotho (the co-receptor of FGF21) or extracellular neutralization of FGF21 only partially attenuates these effects, suggestive of other mechanisms except for autocrine. Mechanistically, intracellular FGF21 interacts with nuclear factor erythroid 2-related factor 2 (NRF2), inhibits its ubiquitin-mediated degradation, and promotes its nuclear translocation. NRF2 directly transcriptionally activates Ins1 , Ins2 and Pdx1 , thereby mediating β -cell function improvement induced by GLP-1 or FGF21. Besides, GLP-1-induced β -cell function improvement is positively correlated with FGF21 and NRF2 levels and is attenuated by β -Klotho antagonism in human islets and islet organoids. These findings uncover a novel noncanonical intracellular FGF21–NRF2 pathway, update the concept of autocrine/intracrine, and identify endogenous β -cell FGF21 enhancement as a promising therapeutic strategy for β -cell function improvement.
科研通智能强力驱动
Strongly Powered by AbleSci AI